Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
SAN DIEGO, Jan. 04, 2018 -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 at 8:30 a.m. PST (11:30 a.m. EST) at the Westin St. Francis Hotel in San Francisco.
A live audio webcast of the presentation and breakout question and answer session will be available through the Events and Presentations page of the company's website (www.otonomy.com).
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]
